Remimazolam Improves the Safety in Elderly Patients Undergoing

Status Not yet recruiting

Clinical Trial Summary

Gastroenteroscopy diagnosis and treatment drugs need to meet the needs of quick onset, quick recovery and less anesthesia complications. Remimazolam is an anesthetic sedative independently developed by China. It is a new short-acting GABA(A) receptor agonist. Remimazolam has the advantages of rapid onset, rapid recovery, antagonist, controllable degree of cardiovascular and respiratory depression, low incidence of hypotension and respiratory depression. However, elderly patients as important and special patients, there are still a lack of relevant studies and reports. In order to verify the safety and effectiveness of remimazolam in the gastroenteroscopy treatment of elderly patients, it can reduce the incidence of intraoperative hypotension or respiratory depression rate, improve the quality of recovery of elderly patients.

Clinical Trial Description

Patients are fasted for at least 6 hours and water for at least 2 hours. After entering the gastroscopic room, patients took 0.1 g of dacronin hydrochloride glue in the throat for about 5 minutes, instructed the patient to be in the left recumbent position and nasal catheter oxygen (4 L / min), finger oxygen and blood pressure ; after static pushing sufentanil 0.08 μg/kg, respectively, give remimazolam or propofol for sedation; MOAA/S score ≤ 3 , start gastrointestinal endoscopy, maintain MOAA/S ≤ 4 during the operation. After the end of gastrointestinal treatment, the patient is moved to the recovery room for recovery. The evaluators also assessed the incidence of blood oxygen saturation < 90%, the incidence of respiratory rate < 8 times/min, the incidence of hypotension, the time of improved aldrete≥9, the time of discharge score ≥9 points, the postoperative cognitive function, amnesia, anxiety, dizziness, pain, nausea, and adverse events. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05406102
Study type	Interventional
Source	First Affiliated Hospital Xi'an Jiaotong University
Contact	Qiang Wang
Phone	0086-02985323646
Email	dr.wangqiang@139.com
Status	Not yet recruiting
Phase	Phase 4
Start date	July 10, 2022
Completion date	June 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05073744` - Nalbuphine Versus Morphine for Perioperative Tumor Ablation	Phase 4
Completed	`NCT03969641` - Safety of RIV4 Versus IIV4 in Pregnant Women	Phase 4
Completed	`NCT05592951` - Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers	N/A
Completed	`NCT04693429` - Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+	Phase 1
Completed	`NCT01636024` - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594	Phase 1
Completed	`NCT01415102` - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.	Phase 1
Completed	`NCT01243502` - A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers	Phase 1
Completed	`NCT06072170` - Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience	Phase 1
Completed	`NCT05076253` - Efficacy of Ivermectin in COVID-19	Phase 1/Phase 2
Recruiting	`NCT06060379` - Giochiamo 626 - Gaming for Health and Safety in Workplaces	N/A
Recruiting	`NCT05298800` - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23	Phase 4
Completed	`NCT05188638` - Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects	Phase 1
Completed	`NCT05145621` - Oral Bio-equivalence Study	Phase 1
Recruiting	`NCT05580159` - New Generation mRNA Booster Vaccine Against Emerging VOCs	Phase 3
Not yet recruiting	`NCT04596956` - Safety and Efficacy of Sodium Bicarbonate Ringer Injection	Phase 4
Completed	`NCT03033329` - Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4	Phase 1
Terminated	`NCT01929811` - NeoMET Study in Neoadjuvant Treatment of Breast Cancer	Phase 2
Completed	`NCT01193335` - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.	Phase 4
Completed	`NCT03300466` - A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds	N/A
Active, not recruiting	`NCT05686161` - mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Remimazolam Improves the Safety in Elderly Patients Undergoing Gastrointestinal Endoscopy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms